Log in

Pfizer Stock Price, Forecast & Analysis (NYSE:PFE)

$37.28
+0.73 (+2.00 %)
(As of 11/17/2019 01:00 AM ET)
Today's Range
$36.52
Now: $37.28
$37.47
50-Day Range
$34.80
MA: $36.68
$38.62
52-Week Range
$33.97
Now: $37.28
$46.47
Volume29.38 million shs
Average Volume18.60 million shs
Market Capitalization$206.31 billion
P/E Ratio12.43
Dividend Yield3.93%
Beta0.67
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP71708110
Phone212-733-2323

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$53.65 billion
Cash Flow$4.29 per share
Book Value$11.81 per share

Profitability

Net Income$11.15 billion

Miscellaneous

Employees92,400
Outstanding Shares5,534,120,000
Market Cap$206.31 billion
Next Earnings Date2/4/2020 (Estimated)
OptionableOptionable

Receive PFE News and Ratings via Email

Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.


Pfizer (NYSE:PFE) Frequently Asked Questions

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer declared a quarterly dividend on Tuesday, September 24th. Stockholders of record on Friday, November 8th will be given a dividend of $0.36 per share on Monday, December 2nd. This represents a $1.44 annualized dividend and a dividend yield of 3.86%. The ex-dividend date is Thursday, November 7th. View Pfizer's Dividend History.

How will Pfizer's stock buyback program work?

Pfizer announced that its board has authorized a stock buyback program on Friday, December 14th 2018, which authorizes the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 3.8% of its stock through open market purchases. Stock buyback programs are often an indication that the company's board believes its stock is undervalued.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) released its quarterly earnings data on Tuesday, October, 29th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.62 by $0.13. The biopharmaceutical company had revenue of $12.68 billion for the quarter, compared to the consensus estimate of $12.37 billion. Pfizer had a net margin of 30.57% and a return on equity of 28.10%. The company's revenue was down 4.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.78 EPS. View Pfizer's Earnings History.

When is Pfizer's next earnings date?

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Pfizer.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer updated its FY19 earnings guidance on Tuesday, October, 29th. The company provided earnings per share (EPS) guidance of $2.94-3.00 for the period, compared to the Thomson Reuters consensus estimate of $2.82. The company issued revenue guidance of $51.2-52.2 billion, compared to the consensus revenue estimate of $51.47 billion.

What price target have analysts set for PFE?

12 Wall Street analysts have issued 12-month price targets for Pfizer's stock. Their forecasts range from $36.00 to $55.00. On average, they anticipate Pfizer's stock price to reach $44.53 in the next year. This suggests a possible upside of 19.4% from the stock's current price. View Analyst Price Targets for Pfizer.

What is the consensus analysts' recommendation for Pfizer?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 8 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pfizer.

What are Wall Street analysts saying about Pfizer stock?

Here are some recent quotes from research analysts about Pfizer stock:
  • 1. According to Zacks Investment Research, "The Consumer Healthcare joint venture with Glaxo, the Array acquisition and the pending merger of Upjohn unit with Mylan, if successful, will make Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. The smaller Pfizer should see better revenue growth as the Lyrica LOE cliff will go away. Pfizer expects continued strong growth of key brands like Ibrance and Eliquis and biosimilars to drive sales in the second half. Pfizer is also strengthening its pipeline and hopes to launch new innovative medicines in the next five years, which can drive long-term growth. However, currency headwinds, weak sales in the sterile injectables portfolio, pricing pressure and some recent negative product developments for Prevnar and Xeljanz, are top-line headwinds. Shares have underperformed the industry this year so far. " (10/1/2019)
  • 2. Cantor Fitzgerald analysts commented, "We reiterate our OW rating and think respectable earnings growth, driven by Innovative Medicines, pipeline advancements, and return of capital to PFE’s shareholders — above the industry average — are all underappreciated. Therefore, we believe multiple expansion and upward earnings revisions should drive PFE shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $53." (2/19/2019)

Has Pfizer been receiving favorable news coverage?

News articles about PFE stock have trended somewhat positive on Saturday, according to InfoTrie. The research group ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Pfizer earned a news impact score of 2.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Pfizer.

Who are some of Pfizer's key competitors?

What other stocks do shareholders of Pfizer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfizer investors own include AT&T (T), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Verizon Communications (VZ), General Electric (GE), Intel (INTC), Bank of America (BAC), Exxon Mobil (XOM), Merck & Co., Inc. (MRK) and AbbVie (ABBV).

Who are Pfizer's key executives?

Pfizer's management team includes the folowing people:
  • Mr. Ian C. Read, Exec. Chairman (Age 65)
  • Mr. Albert Bourla D.V.M., DVM, Ph.D., CEO & Director (Age 57)
  • Mr. Frank A. D'Amelio, CFO & EVP of Global Supply & Bus. Operations (Age 61)
  • Dr. Mikael Dolsten, Chief Scientific Officer & Pres of Worldwide Research, Devel. and Medical (Age 60)
  • Mr. John D. Young, Group Pres & Chief Bus. Officer (Age 54)

Who are Pfizer's major shareholders?

Pfizer's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Massachusetts Financial Services Co. MA (1.00%), Fisher Asset Management LLC (0.82%), Sumitomo Mitsui Trust Holdings Inc. (0.41%), California Public Employees Retirement System (0.38%), Russell Investments Group Ltd. (0.18%) and Rhumbline Advisers (0.16%). Company insiders that own Pfizer stock include Alexander R Mackenzie, Charles H Hill, Dawn Rogers, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Pfizer Inc, Rady A Johnson, Sally Susman, Scott Gottlieb and W Don Cornwell. View Institutional Ownership Trends for Pfizer.

Which major investors are selling Pfizer stock?

PFE stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., California Public Employees Retirement System, Artemis Investment Management LLP, Teacher Retirement System of Texas, Miller Howard Investments Inc. NY, Wedge Capital Management L L P NC, Robeco Institutional Asset Management B.V. and Russell Investments Group Ltd.. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Dawn Rogers, Douglas M Lankler, Frank A Damelio, Mikael Dolsten and Rady A Johnson. View Insider Buying and Selling for Pfizer.

Which major investors are buying Pfizer stock?

PFE stock was purchased by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Eagle Asset Management Inc., Fisher Asset Management LLC, State of Tennessee Treasury Department, Diamond Hill Capital Management Inc., First Trust Advisors LP, Sumitomo Mitsui Trust Holdings Inc. and Foundry Partners LLC. Company insiders that have bought Pfizer stock in the last two years include Pfizer Inc and Scott Gottlieb. View Insider Buying and Selling for Pfizer.

How do I buy shares of Pfizer?

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Pfizer's stock price today?

One share of PFE stock can currently be purchased for approximately $37.28.

How big of a company is Pfizer?

Pfizer has a market capitalization of $206.31 billion and generates $53.65 billion in revenue each year. The biopharmaceutical company earns $11.15 billion in net income (profit) each year or $3.00 on an earnings per share basis. Pfizer employs 92,400 workers across the globe.View Additional Information About Pfizer.

What is Pfizer's official website?

The official website for Pfizer is http://www.pfizer.com/.

How can I contact Pfizer?

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.


MarketBeat Community Rating for Pfizer (NYSE PFE)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  1,318 (Vote Outperform)
Underperform Votes:  893 (Vote Underperform)
Total Votes:  2,211
MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe PFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/17/2019 by MarketBeat.com Staff

Featured Article: Dividend Aristocrat Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel